Detalhe da pesquisa
1.
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Circulation
; 145(19): 1471-1479, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35389229
2.
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
N Engl J Med
; 379(12): 1118-1127, 2018 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30145946
3.
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
N Engl J Med
; 379(14): 1332-1342, 2018 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30146935
4.
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
J Thromb Thrombolysis
; 50(1): 12-19, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32323190
5.
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
J Thromb Thrombolysis
; 50(1): 1-11, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32323191
6.
A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Eur Heart J
; 40(44): 3593-3602, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31461239
7.
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
N Engl J Med
; 368(6): 513-23, 2013 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23388003
8.
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Circulation
; 130(5): 410-8, 2014 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24970782
9.
Laboratory assessment of rivaroxaban: a review.
Thromb J
; 11(1): 11, 2013 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23822763
10.
Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study.
TH Open
; 6(4): e304-e308, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36299620
11.
Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial.
TH Open
; 6(3): e177-e183, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36046208
12.
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
N Engl J Med
; 368(20): 1945-6, 2013 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-23675665
13.
Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
J Am Heart Assoc
; 10(22): e021579, 2021 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34755519
14.
Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients.
J Am Heart Assoc
; 10(5): e019459, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33586478
15.
Assays for measuring rivaroxaban: their suitability and limitations.
Ther Drug Monit
; 32(6): 673-9, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20844464
16.
Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.
TH Open
; 4(1): e59-e65, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32190813
17.
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Thromb Haemost
; 120(3): 515-524, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31975354
18.
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
J Am Coll Cardiol
; 75(25): 3140-3147, 2020 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32586587
19.
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF.
JACC Heart Fail
; 8(5): 359-368, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171760
20.
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.
CPT Pharmacometrics Syst Pharmacol
; 8(11): 805-814, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31276324